Inhibition of MEK/ERK1/2 sensitizes lymphoma cells to sorafenib-induced apoptosis
about
ABT-263 enhances sorafenib-induced apoptosis associated with Akt activity and the expression of Bax and p21((CIP1/WAF1)) in human cancer cells.Sorafenib activates CD95 and promotes autophagy and cell death via Src family kinases in gastrointestinal tumor cells.Dual inhibition of phosphatidylinositol 3-kinase/mammalian target of rapamycin and mitogen activated protein kinase pathways in non-Hodgkin lymphomaSorafenib inhibits lymphoma xenografts by targeting MAPK/ERK and AKT pathways in tumor and vascular cells.The novel anti-MEK small molecule AZD6244 induces BIM-dependent and AKT-independent apoptosis in diffuse large B-cell lymphomaERK1/2 activity contributes to gemcitabine resistance in pancreatic cancer cells.Perifosine and sorafenib combination induces mitochondrial cell death and antitumor effects in NOD/SCID mice with Hodgkin lymphoma cell line xenografts.Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for "vertical" and "lateral" combination strategies.Synergism between bosutinib (SKI-606) and the Chk1 inhibitor (PF-00477736) in highly imatinib-resistant BCR/ABL⁺ leukemia cells.Identification and characterization of a novel chemotype MEK inhibitor able to alter the phosphorylation state of MEK1/2.Modulation of Navitoclax Sensitivity by Dihydroartemisinin-Mediated MCL-1 Repression in BCR-ABL+ B-Lineage Acute Lymphoblastic Leukemia.How Biophysical Forces Regulate Human B Cell Lymphomas.Pan-RAF and MEK vertical inhibition enhances therapeutic response in non-V600 BRAF mutant cells.
P2860
Q33842714-68C6F0BB-070E-4822-83EE-33122E036E3BQ34104350-C655D05A-EB9F-408C-AE85-60EC6C3903DFQ34644692-EC37299C-FFFB-4582-96F7-F760552C794DQ34689078-30EDDCB4-B0C6-4D94-AE44-B8DEC574125CQ35140947-1E81B20C-4498-4E7D-B204-D5A85823DB06Q39169106-886D0029-1CA7-4AFE-8A5E-B6F1D10A1235Q39202496-28E0BC4B-4BC4-4BE6-8FEF-BE2DF57E83EEQ39383689-89FC2D0D-A273-4104-A0D1-BD03FA5DF94AQ40063670-B9699BB9-4E00-4B9A-B52F-85DFC4007D11Q41916599-FAB4D2D9-1D1C-4026-91FF-14C3EB137625Q47858676-952D6005-DEBB-431D-9A94-B2E6BBF4997DQ52593925-F280BD8A-9D8A-4013-B656-4864083804E3Q55086907-3205916E-E71A-4AF1-AC3E-B696631B4316
P2860
Inhibition of MEK/ERK1/2 sensitizes lymphoma cells to sorafenib-induced apoptosis
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Inhibition of MEK/ERK1/2 sensitizes lymphoma cells to sorafenib-induced apoptosis
@ast
Inhibition of MEK/ERK1/2 sensitizes lymphoma cells to sorafenib-induced apoptosis
@en
type
label
Inhibition of MEK/ERK1/2 sensitizes lymphoma cells to sorafenib-induced apoptosis
@ast
Inhibition of MEK/ERK1/2 sensitizes lymphoma cells to sorafenib-induced apoptosis
@en
prefLabel
Inhibition of MEK/ERK1/2 sensitizes lymphoma cells to sorafenib-induced apoptosis
@ast
Inhibition of MEK/ERK1/2 sensitizes lymphoma cells to sorafenib-induced apoptosis
@en
P2093
P2860
P1433
P1476
Inhibition of MEK/ERK1/2 sensitizes lymphoma cells to sorafenib-induced apoptosis
@en
P2093
Jonathan Friedberg
Nicholas Jordan
Richard I Fisher
Steven Grant
Tri K Nguyen
P2860
P304
P356
10.1016/J.LEUKRES.2009.07.013
P50
P577
2010-02-01T00:00:00Z